1. What is the CNMST Exoskeleton? Definition and Role of the National Body
1.1. The CNMST Framework: Who Are They and Why Do They Validate Exoskeletons?
The Caisse Nationale de l'Assurance Maladie des Travailleurs Salariés (CNMST) is a key body within the French Social Security system. Its primary mission is the prevention of occupational risks, particularly workplace accidents and occupational diseases. Within this framework, it assesses and validates personal and collective protective equipment, including exoskeletons, to ensure their effectiveness and safety for employees. The goal is to reduce Musculoskeletal Disorders (MSDs), which are the leading cause of occupational diseases in France, resulting in millions of lost working days each year.
By validating an exoskeleton, the CNMST does more than just grant a quality label. It also opens the door to funding from the Health Insurance – Occupational Risks branch, enabling companies to invest in concrete prevention solutions. This rigorous process involves real-world testing, ergonomic studies, and an evaluation of the benefits for workers. Thus, a CNMST exoskeleton is much more than simple equipment: it is a scientifically validated and financially supported tool for combating MSDs.
1.2. What is a CNMST Exoskeleton?
A CNMST exoskeleton is a wearable device designed to assist workers' movements and reduce the physical strain associated with their professional activities. It is distinctly different from a medical exoskeleton, which is used for rehabilitation or to aid walking for people with disabilities. The CNMST exoskeleton is specifically intended for the prevention of MSDs in the workplace, by relieving the joints and muscles stressed during repetitive tasks or manual handling.
The main types of exoskeletons covered by CNMST validation include:
- CNMST Leg Exoskeleton: Designed to assist leg movements, particularly when working in a squatting, kneeling, or bent position. It reduces muscle fatigue and the risk of knee and hip injuries.
- CNMST Handling Exoskeleton: Intended to relieve the back and shoulders when lifting heavy loads or performing repeated lifting movements. It decreases pressure on the spine and helps prevent lower back pain.
- CNMST Logistics Exoskeleton: Adapted for logistics roles, such as order picking or moving packages. It often combines assistance for the back and arms to reduce overall strain.
These devices are lightweight, adjustable, and designed to be worn for several hours without hindering natural movement. Their validation by the CNMST guarantees they meet strict safety and effectiveness criteria.
2. Validation Criteria for a CNMST Exoskeleton
2.1. Required Technical and Ergonomic Criteria
To be validated by the CNMST, an exoskeleton must meet specific requirements, assessed by prevention experts. These criteria ensure the equipment is not only safe but also effective and suitable for real working conditions. The main criteria include:
- Compliance with Safety Standards: The exoskeleton must be CE certified and comply with ISO 13482, which governs personal service robots, including exoskeletons. This guarantees electrical, mechanical, and thermal safety.
- Demonstrated Effectiveness: The manufacturer must provide scientific evidence of reduced biomechanical strain, measured by sensors or ergonomic studies. For example, a CNMST handling exoskeleton must show a significant decrease in load on the lumbar discs.
- Adaptability: The equipment must be adjustable to different body types (height, weight, build) and various workstations. It must not impede movement or create new risks.
- Comfort and Acceptability: Employees must be able to wear it without major discomfort, skin irritation, or restricted movement. User tests are conducted to assess long-term acceptability.
2.2. Financial Support Criteria
Beyond the technical aspects, the CNMST imposes conditions for an exoskeleton to be eligible for funding from the Health Insurance – Occupational Risks branch. These criteria aim to ensure the investment is part of a comprehensive MSD prevention strategy. The conditions include:
- Funding Eligibility: The exoskeleton must be on the list of equipment validated by the CNMST or approved by a regional CARSAT (Caisse d'Assurance Retraite et de la Santé au Travail).
- Prior Assessment: The company must carry out an MSD risk assessment, often with the help of an ergonomist or occupational physician. This assessment identifies the most exposed workstations and justifies the need for an exoskeleton.
- Prevention Plan: The company must demonstrate that it has implemented an MSD prevention plan, including organisational actions (task rotation, breaks) and technical measures (workstation design). The exoskeleton is a complement, not a standalone solution.
These criteria ensure that funding is allocated to serious projects where the exoskeleton is integrated into a comprehensive prevention strategy.
3. How to Obtain CNMST Funding for an Exoskeleton?
3.1. Funding Application Procedure
Obtaining CNMST funding for an exoskeleton requires following a structured procedure, which may vary slightly by region. Here are the key steps:
- Step 1: MSD Risk Assessment: Identify workstations where MSDs are most common. Use tools like analysis of workplace accidents, employee interviews, or ergonomic observations.
- Step 2: Select a Validated Exoskeleton: Choose a model approved by the CNMST or a CARSAT. Brands like Exyvex offer CNMST handling or leg exoskeletons that meet the criteria.
- Step 3: Prepare the Application File: Gather the necessary supporting documents: a detailed ergonomic study, equipment quote, existing prevention plan, and the manufacturer's certificate of conformity.
- Step 4: Submit to the CARSAT or CRAMIF: Depending on your region, submit your file to the CARSAT (for provincial regions) or the CRAMIF (for Île-de-France). Processing times vary from 2 to 6 months.
The funding amount can cover up to 70% of the total cost of the exoskeleton, in the form of a grant or an interest-free loan. This percentage depends on the size of the company and the severity of the identified risks.
3.2. Is the CNMST Exoskeleton Reimbursed by Social Security?
No, the CNMST exoskeleton is not reimbursed by Social Security in the classic sense. It is not an individual reimbursement for the employee, but rather funding granted to the company via the Occupational Accidents and Diseases (AT/MP) branch of the Health Insurance system. This funding can take the form of:
- A direct grant: The company receives a lump sum or a sum proportional to the equipment's cost.
- An interest-free loan: The company can borrow without interest to finance the purchase, with repayment spread over several years.
The mandatory conditions are that the exoskeleton is used exclusively in a professional setting and contributes to the prevention of MSDs. Companies must also commit to training employees in its use and ensuring regular monitoring.
4. Concrete Benefits for Companies and Employees
4.1. MSD Prevention and Improved Working Conditions
Adopting a CNMST exoskeleton brings tangible benefits for both employees and the company. By reducing physical strain, these devices improve health and well-being at work. The main advantages include:
- Reduced Physical Strain: A CNMST handling exoskeleton relieves the back when lifting loads, while a CNMST leg exoskeleton reduces pressure on the knees during squatting work. Employees experience less fatigue and pain.
- Decreased Absenteeism: MSDs are a major cause of sick leave. By preventing them, the company reduces the number of absence days, improving production continuity.
- Improved Comfort: Modern exoskeletons are lightweight (often under 5 kg) and designed to be worn without discomfort. Employees report a better quality of work life and greater satisfaction.
4.2. Impact on Company Performance
Beyond the human benefits, the CNMST exoskeleton has a positive impact on the company's economic performance. Returns on investment are often rapid, thanks to:
- Lower AT/MP Costs: By reducing workplace accidents and occupational diseases, the company lowers its Health Insurance contributions and compensation costs.
- Increased Productivity: Less fatigued employees are more efficient. Studies show a 10 to 20% increase in productivity at workstations equipped with exoskeletons.
- Enhanced Employer Brand Image: A company that invests in MSD prevention strengthens its attractiveness to talent and improves its reputation.
The key sectors where these benefits are most pronounced are logistics, industry, construction, and healthcare, where repetitive movements and manual handling are common.
5. Differences Between CNMST Exoskeleton and Medical Exoskeleton
5.1. Professional Exoskeleton vs. Medical Exoskeleton
It is essential to distinguish the CNMST exoskeleton, intended for MSD prevention in the workplace, from the medical exoskeleton, used for rehabilitation or walking assistance. Here are the main differences:
- Usage: The CNMST exoskeleton is designed to assist the movements of healthy workers to prevent injuries. The medical exoskeleton is prescribed by a doctor for patients suffering from paralysis, muscle weakness, or neurological disorders.
- Funding: The CNMST exoskeleton is funded by the Health Insurance – Occupational Risks branch via the company. The medical exoskeleton may be covered by individual Health Insurance under a Long-Term Condition (ALD) scheme or by mutual insurance companies.
- Examples: A CNMST walking aid exoskeleton does not exist as such, as the CNMST only funds professional uses. In contrast, a rehabilitation exoskeleton can be used in a rehabilitation centre to help a patient walk again.
This distinction is crucial for companies looking to invest in an exoskeleton: they must turn to models validated by the CNMST to benefit from financial aid.
6. Case Studies and Company Testimonials
6.1. Example in Logistics
A large logistics company adopted a CNMST logistics exoskeleton for its order pickers, who perform thousands of lifting and moving gestures per day. After a six-month trial phase, the results were impressive:
- Reduction in Lower Back Pain: -30% in back-related complaints, measured by health questionnaires.
- Increased Productivity: +15% orders processed per hour, due to reduced fatigue.
- Decreased Absenteeism: MSD-related sick leave dropped by 25%.
The company's safety manager testifies: "The CNMST exoskeleton has transformed our approach to prevention. Employees are more motivated, and the results speak for themselves."
6.2. Example in Industry
In an automotive production plant, a CNMST handling exoskeleton was deployed for line operators who regularly lift heavy parts. Results after one year:
- Fewer Accidents: -50% in MSD-related stoppages, according to the accident register.
- Improved Comfort: 90% of operators reported feeling less tired at the end of the day.
- Return on Investment: The company saved €40,000 in compensation costs in the first year.
One operator testifies: "Since I started wearing the exoskeleton, I no longer have back pain after work. I can focus on my task without suffering."
7. How to Choose a Suitable CNMST Exoskeleton?
7.1. Selection Criteria
Choosing the right CNMST exoskeleton is crucial to maximise the benefits. Here are the criteria to consider:
- Analysis of Workstations: Identify repetitive movements and specific constraints (load handling, working at height, squatting positions). A CNMST leg exoskeleton will be suitable for positions requiring frequent bending, while a CNMST handling exoskeleton will be appropriate for lifting tasks.
- Consult the List of Validated Models:
